192 related articles for article (PubMed ID: 20213094)
1. Role of anti-Her-2 therapy in bladder carcinoma.
Marín AP; Arranz EE; Sánchez AR; Auñón PZ; Barón MG
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1915-20. PubMed ID: 20213094
[TBL] [Abstract][Full Text] [Related]
2. HER-2 signaling and inhibition in breast cancer.
Browne BC; O'Brien N; Duffy MJ; Crown J; O'Donovan N
Curr Cancer Drug Targets; 2009 May; 9(3):419-38. PubMed ID: 19442060
[TBL] [Abstract][Full Text] [Related]
3. Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Flaherty KT; Brose MS
Curr Oncol Rep; 2006 Mar; 8(2):90-5. PubMed ID: 16507217
[TBL] [Abstract][Full Text] [Related]
4. HER-2-positive breast cancer: hope beyond trastuzumab.
Bartsch R; Wenzel C; Zielinski CC; Steger GG
BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients.
Salzberg M; Borner M; Bauer JA; Morant R; Rauch D; Rochlitz C
Eur J Cancer; 2006 Oct; 42(15):2660-1. PubMed ID: 16934972
[No Abstract] [Full Text] [Related]
6. [Targeted therapy for locally advanced and/or metastatic bladder cancer].
Wallerand H; Robert G; Bernhard JC; Ravaud A; Ferrière JM
Prog Urol; 2008 Jul; 18(7):407-17. PubMed ID: 18602599
[TBL] [Abstract][Full Text] [Related]
7. Targeting Her-2/neu in breast cancer: as easy as this!
Azim H; Azim HA
Oncology; 2008; 74(3-4):150-7. PubMed ID: 18708732
[TBL] [Abstract][Full Text] [Related]
8. [Use of trastuzumab in the therapy of breast cancer].
Riemer AB; Zielinski CC
Ther Umsch; 2008 Apr; 65(4):217-22. PubMed ID: 18622914
[TBL] [Abstract][Full Text] [Related]
9. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
[TBL] [Abstract][Full Text] [Related]
11. HER2 as a target for breast cancer therapy.
Tagliabue E; Balsari A; Campiglio M; Pupa SM
Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
[TBL] [Abstract][Full Text] [Related]
12. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
13. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab in gastric cancer.
Okines AF; Cunningham D
Eur J Cancer; 2010 Jul; 46(11):1949-59. PubMed ID: 20542421
[TBL] [Abstract][Full Text] [Related]
15. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
16. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
[TBL] [Abstract][Full Text] [Related]
17. [Targeted therapy for metastatic bladder cancer].
Vom Dorp F; Börgermann C; Rose A; Becker M; Rübben H
Urologe A; 2008 Oct; 47(10):1311-4. PubMed ID: 18587555
[TBL] [Abstract][Full Text] [Related]
18. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
[TBL] [Abstract][Full Text] [Related]
19. [Management of metastatic HER2-positive breast cancer: present and future].
Guiu S; Coudert B; Favier L; Arnould L; Fumoleau P
Bull Cancer; 2010 Mar; 97(3):365-83. PubMed ID: 20176546
[TBL] [Abstract][Full Text] [Related]
20. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]